Genetic engineering of pigs to provide organs for xenotransplantation

Current Opinion in Organ Transplantation

Volumn 11, Issue 2, 2006, Pages 160-165

  White, David J G ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Gal 1,3Gal; Nuclear transfer embryo transfer; Transgenic pig; Xenotransplantation; 1,3 galactosyltransferase gene knockout

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; CYCLOSPORIN; MONOCLONAL ANTIBODY; REGULATOR PROTEIN;

BABOON; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC MANIPULATION; GRAFT REJECTION; GRAFT SURVIVAL; HISTOLOGY; HUMAN; IMMUNOGENETICS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; KNOCKOUT GENE; MEDICAL TECHNOLOGY; NONHUMAN; ORGAN DONOR; ORGAN TRANSPLANTATION; PRIMATE; REVIEW; SURVIVAL TIME; SWINE; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSGENIC MOUSE; TRANSGENICS; XENOGRAFT; XENOTRANSPLANTATION;

EID: 33645826074     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Palmiter RD, Brinster RL, Hammer RE, et al. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature 1982; 300:611-615.
2. Brinster RL, Chen HY, Trumbauer M, et al. Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs. Cell 1981; 27:223-231.
3. Costantini F, Lacy E. Introduction of a rabbit beta-globin gene into the mouse germ line. Nature 1981; 294:92-94.
4. Gordon JW, Scangos GA, Plotkin DJ, et al. Genetic transformation of mouse embryos by microinjection of purified DNA. Proc Natl Acad Sci U S A 1980; 77:7380-7384.
5. Wagner TE, Hoppe PC, Jollick JD, et al. Microinjection of a rabbit beta-globin gene into zygotes and its subsequent expression in adult mice and their offspring. Proc Natl Acad Sci U S A 1981; 78:6376-6380.
6. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981; 292:154-156.
7. Bradley A, Evans M, Kaufman MH, et al. Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines. Nature 1984; 309:255-256.
8. Doetschman T, Gregg RG, Maeda N, et al. Targeted correction of a mutant HPRT gene in mouse embryonic stem cells. Nature 1987; 330:576-578.
9. Thomas KR, Capecchi MR. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 1987; 51:503-512.
10. Wilmut I, Schnieke AE, McWhir J, et al. Viable offspring derived from fetal and adult mammalian cells. Nature 1997; 385:810-813.
11. Polejaeva IA, Chen SH, Vaught TD, et al. Cloned pigs produced by nuclear transfer from adult somatic cells. Nature 2000; 407:86-90.
12. Park KW, Cheong HT, Lai L, et al. Production of nuclear transfer-derived swine that express the enhanced green fluorescent protein. Anim Biotechnol 2001; 12:173-181.
13. Schnieke AE, Kind AJ, Ritchie WA, et al. Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts. Science 1997; 278:2130-2133.
14. Kato Y, Tani T, Sotomaru Y, et al. Eight calves cloned from somatic cells of a single adult. Science 1998; 282:2095-2098.
15. Baguisi A, Behboodi E, Melican DT, et al. Production of goats by somatic cell nuclear transfer. Nat Biotechnol 1999; 17:456-461.
16. McCreath KJ, Howcroft J, Campbell KH, et al. Production of gene-targeted sheep by nuclear transfer from cultured somatic cells. Nature 2000; 405:1066-1069.
17. Dai Y, Vaught TD, Boone J, et al. Targeted disruption of the alpha1,3-galactosyltransferase gene in cloned pigs. Nat Biotechnol 2002; 20:251-255.
18. Lai L, Kolber-Simonds D, Park KW, et al. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 2002; 295:1089-1092.
19. Phelps CJ, Koike C, Vaught TD, et al. Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003; 299:411-414.
20. Atkinson JP, Oglesby TJ, White D, et al. Separation of self from non-self in the complement system: a role for membrane cofactor protein and decay accelerating factor. Clin Exp Immunol 1991; 86 (Suppl 1):27-30.
21. Dalmasso AP, Platt JL, Bach FH. Reaction of complement with endothelial cells in a model of xenotransplantation. Clin Exp Immunol 1991; 86 (Suppl 1):31-35.
22. Capey S, van den Berg CW. Porcine complement regulators protect aortic smooth muscle cells poorly against human complement-induced lysis and proliferation: consequences for xenotransplantation. Xenotransplantation 2005; 12:217-226. This paper reports that the distribution of porcine CD55 in pigs is not as it is in humans, and is absent from aortic smooth muscle. Although, it provides no data, it also reports that porcine CD55 is not expressed on porcine endothelium. We can confirm this from our own studies.
23. Harrower TP, Richards A, Cruz G, et al. Complement regulatory proteins are expressed at low levels in embryonic human, wild type and transgenic porcine neural tissue. Xenotransplantation 2004; 11:60-71. Another publication describing aberrant CD55 expression in pigs.
24. Perez de la Lastra JM, Harris CL, Hinchliffe SJ, et al. Pigs express multiple forms of decay-accelerating factor (CD55), all of which contain only three short consensus repeats. J Immunol 2000; 165:2563-2573.
25. Richards AC, Davies HF, McLaughlin ML, et al. Serum anti-pig antibodies as potential indicators of acute humoral xenograft rejection in pig-to-cynomolgus monkey kidney transplantation. Transplantation 2002; 73:881-889.
26. Baumann BC, Forte P, Hawley RJ, et al. Lack of galactose-alpha-1,3- galactose expression on porcine endothelial cells prevents complement-induced lysis but not direct xenogeneic NK cytotoxicity. J Immunol 2004; 172:6460-6467. This paper demonstrates that Gal is not the target for natural killer cytotoxicity.
27. Wang H, DeVries ME, Deng S, et al. The axis of interleukin 12 and gamma interferon regulates acute vascular xenogeneic rejection. Nat Med 2000; 6:549-555.
28. Johnston PS, Wang MW, Lim SM, et al. Discordant xenograft rejection in an antibody-free model. Transplantation 1992; 54:573-576.
29. Oglesby TJ, White DJG, Tedja I, et al. Protection of mammalian cells from complement-mediated lysis by transfection of human membrane cofactor and decay accelerating factor. Trans Assoc Am Phys 1991; 104:164-172.
30. Cary N, Moody J, Yannoutsos N, et al. Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice: a potential approach to inhibition of hyperacute xenograft rejection. Transplant Proc 1993; 25:400-401.
31. Yannoutsos N, Ijzermans JN, Harkes C, et al. A membrane cofactor protein transgenic mouse model for the study of discordant xenograft rejection. Genes Cells 1996; 1:409-419.
32. Dalmasso AP, Vercellotti GM, Platt JL, et al. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor: potential for prevention of xenograft hyperacute rejection. Transplantation 1991; 52:530-533.
33. Wang MW, Wright LJ, Sims MJ, et al. Presence of human chromosome 1 with expression of human decay-accelerating factor (DAF) prevents lysis of mouse/human hybrid cells by human complement. Scand J Immunol 1991; 34:771-778.
34. Carrington CA, Richards AC, Cozzi E, et al. Expression of human DAF and MCP on pig endothelial cells protects from human complement. Transplant Proc 1995; 27:321-323.
35. Cozzi E, White DJ. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1:964-966.
36. Loveland BE, Milland J, Kyriakou P, et al. Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons. Xenotransplantation 2004; 11:171-183. This is a meticulous study of the protective effect of a complement regulator on xenograft rejection in nonimmunosuppressed baboons.
37. Zhao Y, Rodriguez-Barbosa JI, Swenson K, et al. The induction of specific pig skin graft tolerance by grafting with neonatal pig thymus in thymectomized mice. Transplantation 2000; 69:1447-1451.
38. Barth RN, Yamamoto S, LaMattina JC, et al. Xenogeneic thymokidney and thymic tissue transplantation in a pig-to-baboon model. I: Evidence for pig-specific T-cell unresponsiveness. Transplantation 2003; 75:1615-1624.
39. Brenner P, Schmoeckel M, Wimmer C, et al. Mean xenograft survival of 14.6 days in a small group of hDAF-transgenic pig hearts transplanted orthotopically into baboons. Transplant Proc 2005; 37:472-476.
40. Garcia B, Sun HT, Yang HJ, et al. Xenotransplantation of human decay accelerating factor transgenic porcine kidney to non-human primates: 4 years experience at a Canadian center. Transplant Proc 2004; 36:1714-1716. This paper reviews the different immunosuppressive protocols that are successful in preventing the rejection of transgenic pig kidneys in baboons.
41. McGregor CG, Davies WR, Oi K, et al. Cardiac xenotransplantation: recent preclinical progress with 3-month median survival. J Thorac Cardiovasc Surg 2005; 130:844-851. Documents the best series of pig to baboon xenograft survival to date. There does not seem to be anything novel as far as the transgene is concerned, but the paper emphasizes attention to detailed immunosuppressive management.
42. Menoret S, Plat M, Blancho G, et al. Characterization of human CD55 and CD59 transgenic pigs and kidney xenotransplantation in the pig-to-baboon combination. Transplantation 2004; 77:1468-1471. Another paper documenting rejection of transgenic pig kidneys in nonimmunosuppressed baboons. Emphasizes the occurrence of coagulopathy at the time of rejection.
43. Manez R, Lopez-Pelaez E, Centeno A, et al. Transgenic expression in pig hearts of both human decay-accelerating factor and human membrane cofactor protein does not provide an additional benefit to that of human decay-accelerating factor alone in pig-to-baboon xenotransplantation. Transplantation 2004; 78:930-933. The title is fully descriptive; however, the immunosuppressive protocol used was perhaps not appropriate for the overall goal of the study.
44. Zhou CY, Mclnnes E, Copeman L, et al. Transgenic pigs expressing human CD59, in combination with human membrane cofactor protein and human decay-accelerating factor. Xenotransplantation 2005; 12:142-148. An in-vitro study showing the protective advantage of using a triple transgenic pig in preventing complement lysis.
45. Lai L, Kolber-Simonds D, Park KW, et al. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 2002; 295:1089-1092.
46. Phelps CJ, Koike C, Vaught TD, et al. Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003; 299:411-414.
47. Kolber-Simonds D, Lai L, Watt SR, et al. Production of alpha-1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations. Proc Natl Acad Sci U S A 2004; 101:7335-7340.
48. Ramsoondar JJ, Machaty Z, Costa C, et al. Production of alpha 1,3-galactosyltransferase-knockout cloned pigs expressing human alpha 1,2-fucosylosyltransferase. Biol Reprod 2003; 69:437-445.
49. Takahagi Y, Fujimura T, Miyagawa S, et al. Production of alpha 1,3-galactosyltransferase gene knockout pigs expressing both human decay-accelerating factor and N-acetylglucosaminyltransferase III. Mol Reprod Dev 2005; 71:331-338.
50. Harrison S, Boquest A, Grupen C, et al. An efficient method for producing alpha(1,3)-galactosyltransferase gene knockout pigs. Cloning Stem Cells 2004; 6:327-331.
51. Kuwaki K, Tseng YL, Dor FJ, et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005; 11:29-31. A milestone paper in that it records the first results from transplanting Gal knockout hearts into baboons with survivals ranging from 2 to 6 months (median 78 days). These results have to be encouraging for the future of xenotransplantation.
52. Yamada K, Yazawa K, Shimizu A, et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3- galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 2005; 11:32-34. From the same group as above, this paper reports the equally encouraging results with kidney transplants from knockout pigs into baboons. In this study the authors used their 'thymokidney' technique, and report absence of acute vascular rejection in all the grafts.
53. Chen G, Starzl T, Sun HT, et al. Induced anti-non-Gal antibodies lead to acute humoral rejection in baboons using α1, 3-galactosyltransferase gene-knockout pigs as kidney donors. Nat Med (in press).
54. Schroeder C, Allan JS, Nguyen BN, et al. Hyperacute rejection is attenuated in GalT knockout swine lungs perfused ex vivo with human blood. Transplant Proc 2005; 37:512-513.
55. Yamada K. Life-supporting pig-to-baboon renal transplantation using GalT knockout donors: benefit of cotransplanting a vascularized donor thymic graft. Kidney Int 2005; 68:1971. An in-depth analysis of the thymokidney approach to xenotransplantation.
56. Ghanekar A, Mendicino M, Liu H, et al. Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection. J Immunol 2004; 172:5693-5701. This study elegantly demonstrates the importance of suppressing fgl2 in prolonging xenograft survival using a knockout mouse-to-rat model. Reports the elimination of thrombin deposition.
57. Chen D, Weber M, McVey JH, et al. Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. Am J Transplant 2004; 4:1958-1963. A most remarkable set of results. Expression of tissue factor pathway inhibitor or hirudin results in the elimination of AVR. Cyclosporine immunosuppression resulted in indefinite graft survival in a mouse-to-rat model. Will it be that easy in a pig-to-baboon transplant?
58. Tu CF, Hsieh SL, Lee JM, et al. Successful generation of transgenic pigs for human decay-accelerating factor and human leucocyte antigen DQ. Transplant Proc 2000; 32:913-915.